Associations between circulating inflammatory markers and left ventricular systolic function in liver transplant recipients
Introduction Cardiovascular disease, including heart failure, is one of the leading causes of morbidity and mortality among liver transplant recipients. Inflammatory markers are associated with heart failure in the general population. We aimed to assess whether high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, and soluble (s)CD163 were associated with left ventricular (LV) systolic function in liver transplant recipients. Methods In this cross-sectional study adult liver transplant recipients from the Danish Comorbidity in Liver Transplant Recipients (DACOLT) study who underwent research transthoracic echocardiography and measurements of hs-CRP, IL-6, and sCD163 were included. Outcomes were LV global longitudinal strain (LV GLS), LV ejection fraction (LVEF), and LV systolic dysfunction, defined as LV GLS <16% and/or LVEF <50%. Results We included 317 participants. Median LV GLS was 18.4% (IQR: 16.4-20.1), median LVEF was 54.0% (IQR: 50.0-57.0), and the prevalence of LV systolic dysfunction was 31.5%. In unadjusted analyses, each doubling of hs-CRP, IL-6, and sCD163 were associated with lower LV GLS with associations of -0.29% (95% CI: [-0.50; -0.08], p=0.008), -0.38% (95% CI: [-0.63; -0.13], p=0.003), and -0.37% (95% CI: [-0.73; -0.02], p=0.041), respectively. Associations with LVEF in unadjusted analyses were -0.61% (95% CI: [-1.02; -0.20], p=0.004), -0.86% (95% CI: [-1.34; -0.38], p=0.001), and -0.37% (95% CI: [-1.07;0.33], p=0.297) per doubling of hs-CRP, IL-6 and sCD163, respectively. However, in models adjusting for sex, age, BMI, and smoking status these associations were attenuated. Conclusion Higher levels of the circulating inflammatory markers hs-CRP, IL-6, and sCD163 were associated with LV systolic function in liver transplant recipients. However, these associations were attenuated in adjusted analyses and thus seem to be explained by traditional cardiovascular risk factors. Prospective studies are needed to determine whether inflammatory markers can improve risk stratification and identify those at increased risk of LV systolic dysfunction and heart failure. Clinical trial registration ClinicalTrials.gov , identifier NCT04777032.
Authors
- Jesper J. Linde (ORCID: https://orcid.org/0000-0002-2101-5098)
- Ask Bock (ORCID: https://orcid.org/0000-0002-0382-4705)
- Susanne Dam Nielsen (ORCID: https://orcid.org/0000-0001-6391-7455)
- Emilie Høegholm Ernst Lauridsen (ORCID: https://orcid.org/0009-0006-1250-9164)
- Anne Jensen (ORCID: https://orcid.org/0000-0001-8311-8693)
- Jens Hillingsø (ORCID: https://orcid.org/0000-0002-2381-7836)
- Jens Otto Clemmesen
- Thomas R. Holtveg
- Henning Grønbæk
- Hans-Christian Pommergaard
- Nicoline Arentoft
- Annette Dam Fialla
- Sofie Larsen Øland
- Peter Holland-Fischer
- Tor Biering-Sørensen
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fimmu.2026.1923823
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00